Clinical trial

Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis

NCT03983252

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2021-12-01

PhasePHASE1 / PHASE2

Study timeline

Study start (estimated)2021-12-01Date precision: month

Registry last updated2025-10-20

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple Sclerosisunresolved

Interventions

[F-18]PBR06DRUG

Sponsors & collaborators

Brigham and Women's Hospitallead sponsor

Genzyme, a Sanofi Companycollaborator

Mapped research locations

BostonMassachusetts, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03983252 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.